Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats

British Journal of Pharmacology

Volumn 122, Issue 8, 1997, Pages 1694-1701

  Gardiner, S M ^a   Kemp, P A ^a   Brunner Ferber, F ^b   Bennett, T ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Clinical Pharmacology   (France)

Author keywords

Dual metallopeptidase inhibitor; Enalaprilat; MDL 100,240; Transgenic rats

Indexed keywords

7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ANTIHYPERTENSIVE AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ICATIBANT; METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HEART HEMODYNAMICS; HEART INDEX; HEMODYNAMICS; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEG BLOOD FLOW; MALE; MESENTERY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BENZAZEPINES; BRADYKININ; ENALAPRILAT; HEMODYNAMIC PROCESSES; HYPERTENSION; MALE; METALLOENDOPEPTIDASES; PROTEASE INHIBITORS; PYRIDINES; RATS;

EID: 0031434320     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701551     Document Type: Article

References (37)

1. BADER, M., ZHAO, Y., SANDER, M., LEE, M.A., BACKMANN, J., BOHM, M., DJAVIDANI, B., PETERS, J., MULLINS, J.J. & GANTEN, D. (1992). Role of tissue renin in the pathophysiology of hypertension in TGR (mREN2)27 rats. Hypertension, 19, 681-686.
2. BAO, G., GOHLKE, P., QADRI, F. & UNGER, T. (1992). Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension, 20, 74-79.
3. BAO, G., QADRI, F., STAUSS, B., STAUSS, H., GOHLKE, P. & UNGER, T. (1991). Hoe 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur. J. Pharmacol., 200, 179-182.
4. BENETOS, A., GAVRAS, H., STEWART, J.M., VAVREK, R.J., HATINOGLOU, S. & GAVRAS, I. (1986). Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension, 8, 971-974.
5. CARBONELL, L.F., CARRETERO, O.A., STEWART, J.M. & SCICLI, A.G. (1988). Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension, 11, 239-243.
6. CHEN, K., ZHANG, X., DUNHAM, E.W. & ZIMMERMAN, B.G. (1996). Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension. Hypertension, 27, 85-89.
7. DANCKWARDT, L., SHIMIZU, I., BONNER, G., RETTIG, R. & UNGER, T. (1990). Converting enzyme inhibition in kinin-deficient brown Norway rats. Hypertension, 16, 429-435.
8. ERDÖS, E.G. (1990). Some old and some new ideas on kinin metabolism. J. Cardiovasc. Pharmacol., 15, S20-S24.
9. FRENCH, J.F., ANDERSON, B.A., DOWNS, T.R. & DAGE, R.C. (1995). Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J. Cardiovasc. Pharmacol., 26, 107-113.
10. FRENCH, J.F., FLYNN, G.A., GIROUX, E.L., MEHDI, S., ANDERSON, B., BEACH, D.C., KOEHL, J.R. & DAGE, R.C. (1994). Characterisation of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J. Pharmacol. Exp. Ther., 288, 180-186.
11. G-nitro-L-arginine methyl ester. Br. J. Pharmacol., 101, 632-639.
12. GARDINER, S.M., MARCH, J.E., KEMP, P.A., MULLINS, J.J. & BENNETT, T. (1995). Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br. J. Pharmacol., 116, 2237-2244.
13. GARDINER, S.M., KEMP, P.A., BRUNNER-FERBER, F. & BENNETT, T. (1997). Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats. Br. J. Pharmacol., (in press).
14. HIRTH-DIETRICH, C., STASCH, J-P., GANTEN, D. & LUFT, F.C. (1994). Renal effects of captopril and nitrendipine in transgenic rats with an extra renin gene. Hypertension, 23, 626-631.
15. KENNY, A.J., BOURNE, A. & INGRAM, J. (1993). Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J., 291, 83-88.
16. LAPPE, R.W. (1988). The in vivo vascular actions of atrial natriuretic factor. In Advances in Atrial Peptide Research, ed. Brenner, B.M. & Laragh, J.H. Vol II, pp. 91-100. New York: Raven Press.
17. 2)27. Am. J. Physiol., 270, E919-E929.
18. LUQUE, M., MARTIN, P., MARTELL, N., FERNANDEZ, C., BROSNIHAN, K.B. & FERRARIO, C.M. (1996). Effects of captopril related to increased levels of prostacyclin and angiotensin- (1-7) in essential hypertension. J. Hypertens., 14, 799-805.
19. MORIGUCHI, M., BROSNIHAN, K.B., KUMAGAI, H., GANTEN, D. & FERRARIO, C.M. (1994). Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am. J. Physiol., 266, R1273-R1279.
20. MULLER, A.F., GARDINER, S.M., COMPTON, A.M. & BENNETT, T. (1990). Regional haemodynamic effects of captopril, enalaprilat and lisinopril in conscious water-replete and water-deprived Brattleboro rats. Clin. Sci., 79, 393-401.
21. MULLINS, J.J., PETERS, J. & GANTEN, D. (1990). Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature, 344, 541-544.
22. NORMAN, J.A., LITTLE, D., BOLGAR, M. & DI DONATO, G. (1991). Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem. Biophys. Res. Commun., 175, 22-30.
23. +-depleted marmosets. Am. J. Physiol., 269, H1221-H1228.
24. PHAM, I., GONZALEZ, W., DOUCET, J., FOURNIÉ-ZALUSKI, M-C., ROQUES, B.P. && MICHEL, J-B. (1996). Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin. Eur. J. Pharmacol., 296, 267-276.
25. PHAM, I., GONZALEZ, W., EL AMRANI, A-I., FOURNIÉ-ZALUSKI, M-C., PHILIPPE, M., LABOULANDINE, I., ROQUES, B.P. & MICHEL, J-B. (1993). Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J. Pharmacol. Exp. Ther., 265, 1339-1347.
26. PHAM, I., LÉVY, B., FOURNIÉ-ZALUSKI, M-C., POITEVIN, P., ROQUES, B.P. & MICHEL, J.B. (1995). Acute hemodynamic effects of combined inhibition of neutral endopeptidase and angiotensin converting enzyme in spontaneously hypertensive rats. Fundam. Clin. Pharmacol., 9, 153-160.
27. RICHARDS, A.M., WITTERT, G.A., ESPINER, E.A., YANDLE, T.G., IKRAM, H. & FRAMPTON, C. (1992). Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ. Res., 71, 1501-1507.
28. ROQUES, B.P., NOBLE, F., DAUGE, V., FOURNIÉ-ZALUSKI, M-C. & BEAUMONT, A. (1993). Neutal endopeptidase 24.11. Structure, inhibition, experimental and clinical pharmacology. Pharmacol. Rev., 45, 87-147.
29. SEYMOUR, A.A., ASAAD, M.M., ABBOA-OFFEI, B.E., ROVNYAK, P.L., FENNELL, S. & ROGERS, W.L. (1992). Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats. J. Pharmacol. Exp. Ther., 262, 60-70.
30. SEYMOUR, A.A., SWERDEL, J.M. & ABBOA-OFFEI, B. (1991). Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J. Cardiovasc. Pharmacol., 17, 456-465.
31. STEVENS, T.L., WEI, C-M., AAHRUS, L.L., HEUBLEIN, D.M., KINOSHITA, M., MATSUDA, Y. & BURNETT, J.C. Jr. (1994). Modulation of exogenous and endogenous atrial natriuretic peptide by a receptor inhibitor. Hypertension, 23, 613-618.
32. SUPAPORN, T., WENNBERG, P.W., WEI, C-M., KINOSHITA, M., MATSUDA, Y. & CURNETT, J.C. (1996). Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Clin. Sci., 90, 357-362.
33. TRIPPODO, N.C., PANCHAL, B.C. & FOX, M. (1995a). Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J. Pharmacol. Exp. Ther., 272, 619-627.
34. TRIPPODO, N.C., ROBL, J.A., ASAAD, M.M., BIRD, I.E., PANCHAL, B.C., SCHAEFFER, T.R., FOX, M., GIANCARLI, M.R. & CHEUNG, H.S. (1995b). Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J. Pharmacol. Exp. Ther., 275, 745-752.
35. VERA, W.G., FOURNIÉ-ZALUSKI, M-C., PHAM, I., LABOULANDINE, I., ROQUES, B-P. & MICHEL, J-B. (1995). Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J. Pharmacol. Exp. Ther., 272, 343-351.
36. WEBB, D.J. (1997). Endothelin: from molecule to man. Br. J. Clin. Pharmacol., 44, 9-20.
37. WIRTH, K., HOCK, F.J., ALBUS, U., LINZ, W., ALPERMANN, H.G., ANAGNOSTOPOULOS, H., HENKE, S., BREIPOHL, G., KÖNIG, W., KNOLLE, J. & SCHÖLKENS, B.A. (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol., 102, 774-777.